3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
69
Carcinoma, Non-Small-Cell Lung
62
Stomach Neoplasms
32
Prostatic Neoplasms
21
Nasopharyngeal Carcinoma
20
Lung Neoplasms
20
Squamous Cell Carcinoma of Head and Neck
11
Esophageal Neoplasms
11
Neoplasm Metastasis
8
Head and Neck Neoplasms
7
Inflammatory Breast Neoplasms
6
Pancreatic Neoplasms
5
Neoplasms
5
HER2-positive Breast Cancer
5
Adenocarcinoma
5
Triple Negative Breast Neoplasms
4
Ovarian Neoplasms
4
NSCLC
4
Carcinoma, Squamous Cell
4
Sarcoma
3
Nasopharyngeal Neoplasms
3
Hypopharyngeal Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Carcinoma, Ovarian Epithelial
3
Breast Diseases
3
Adenocarcinoma of Lung
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Tongue Neoplasms
2
Squamous Cell Lung Cancer
2
Interventions
apatinib
2
Injections
2
Carboplatin
2
toripalimab
1
sintilimab
1
camrelizumab
1
Vinorelbine
1
Ultrasonography
1
TNFSF10 protein, human
1
Sodium Chloride
1
Pemetrexed
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Docetaxel
1
Bevacizumab
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Thoracic Neoplasms
×
Docetaxel
×
Clear all
NCT03402048
2020-11-04
EPIC
University of Turin, Italy
Phase 3
Unknown
567 enrolled